Saw this in an E-mail I receivedThought it might be of interest:
In such a competitive landscape especially considering the record 40 new ADC drugs moving from preclinical to clinical this year – which is already surpassing the record-breaking number in 2021, developers are reiterating the challenge of keeping updated with everything that’s going on.
Our Beacon ADC platform currently tracks over 1465 drug conjugate programmes being developed by over 560 different companies, of which 919 are ADCs. To breakdown that landscape further, here are some of the latest updates:
· 168 of ADC drugs are clinically active (18%)
· 447 of ADC drugs are preclinical (48%)
· In the last quarter 71 new ADC drugs have been disclosed
· 442 ADC programs have disclosed preclinical data (47%)
· BLA filings for two ADCs, mirvetuximab soravtansine and trastuzumab duocarmazine, have been submitted to the FDA this year with at least one expected to be approved by the end of 2022.